Send the completed form
to [email protected]om
Direct your patients to visit
abrilada.ca for more information
Send the completed form to [email protected]
Direct your patients to visit
cibinqo.ca for more information
Send the completed form
to [email protected]om
Direct your patients to visit
inflectra.ca for more information
Send the completed form
to [email protected]om
Direct your patients to visit
ruxience.ca for more information
Send the completed form
to [email protected]om
Direct your patients to visit
xeljanz.ca for more information
PrABRILADA® (adalimumab)
For more information:
Please consult the Product Monograph at http://pfizer.ca/pm/en/ABRILADA.pdf for important information relating to other indications, contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.
PrCIBINQO® (abrocitinib)
For more information:
Please consult the Product Monograph at http://pfizer.ca/pm/en/CIBINQO.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.
PrINFLECTRA® (infliximab)
For more information:
Please consult the Product Monograph at http://pfizer.ca/pm/en/INFLECTRA.pdf for important information relating to other indications, contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.
PrRUXIENCE® (rituximab)
For more information:
Please consult the Product Monograph at http://pfizer.ca/pm/en/RUXIENCE.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.
PrXELJANZ® XR / PrXELJANZ® (tofacitinib)
For more information:
Please consult the Product Monograph at http://pfizer.ca/pm/en/XELJANZ.pdf and an Important Safety Information Advisory available at https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2021/75315a-eng.php for important information relating to other indications, contraindications, warnings, precautions, adverse reactions,interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.